Introduction

This chapter explores the recent success and valuation of Novo Nordisk, discussing their strong profits from anti-obesity and diabetes drugs and the impact of their corporate structure as a non-profit foundation on research advances.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app